Suppr超能文献

肿瘤异种移植中血管口径的 MRI 测量:与血管腐蚀铸造的比较。

MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting.

机构信息

CR-UK & EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, 15 Cotswold Road Sutton, Surrey, SM2 5NG, UK.

出版信息

Microvasc Res. 2012 Nov;84(3):323-9. doi: 10.1016/j.mvr.2012.08.001. Epub 2012 Aug 18.

Abstract

Vessel size index (R(v), μm) has been proposed as a quantitative magnetic resonance imaging (MRI) derived imaging biomarker in oncology, for the non-invasive assessment of tumour blood vessel architecture and vascular targeted therapies. Appropriate pre-clinical evaluation of R(v) in animal tumour models will improve the interpretation and guide the introduction of the biomarker into clinical studies. The objective of this study was to compare R(v) measured in vivo with vessel size measurements from high-resolution X-ray computed tomography (μCT) of vascular corrosion casts measured post mortem from the same tumours, with and without vascular targeted therapy. MRI measurements were first acquired from subcutaneous SW1222 colorectal xenografts in mice following treatment with 0 (n=6), 30 (n=6) or 200 mg/kg (n=3) of the vascular disrupting agent ZD6126. The mice were then immediately infused with a low viscosity resin and, following polymerisation and maceration of surrounding tissues, the resulting tumour vascular casts were dissected and subsequently imaged using an optimised μCT imaging approach. Vessel diameters were not measurable by μCT in the 200 mg/kg group as the high dose of ZD6126 precluded delivery of the resin to the tumour vascular bed. The mean R(v) for the three treatment groups was 24, 23 and 23.5 μm respectively; the corresponding μCT measurements from corrosion casts from the 0 and 30 mg/kg cohorts were 25 and 28 μm. The strong association between the in vivo MRI and post mortem μCT values supports the use of R(v) as an imaging biomarker in clinical trials of investigational vascular targeted therapies.

摘要

血管大小指数(R(v),μm)已被提议作为一种定量磁共振成像(MRI)衍生的影像学生物标志物,用于非侵入性评估肿瘤血管结构和血管靶向治疗。在动物肿瘤模型中对 R(v)进行适当的临床前评估将改善对生物标志物的解释并指导其引入临床研究。本研究的目的是比较经血管靶向治疗和未经治疗的同一肿瘤死后血管腐蚀铸型的高分辨率 X 射线计算机断层扫描(μCT)测量的血管大小测量值与体内测量的 R(v)。首先,在接受 0(n=6)、30(n=6)或 200 mg/kg(n=3)血管破坏剂 ZD6126 治疗的小鼠皮下 SW1222 结直肠异种移植瘤中获得 MRI 测量值。然后,立即向小鼠输注低粘度树脂,在周围组织聚合和浸软后,对肿瘤血管铸型进行解剖,并使用优化的 μCT 成像方法对其进行成像。由于高剂量的 ZD6126 阻止了树脂输送到肿瘤血管床,因此在 200 mg/kg 组中无法通过 μCT 测量血管直径。三个治疗组的平均 R(v)分别为 24、23 和 23.5 μm;来自 0 和 30 mg/kg 队列的腐蚀铸型的相应 μCT 测量值分别为 25 和 28 μm。体内 MRI 与死后 μCT 值之间的强相关性支持将 R(v)作为血管靶向治疗临床试验中的影像学生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7158/3657196/fe4736b4d4bd/gr1.jpg

相似文献

引用本文的文献

5
Functional MRI and CT biomarkers in oncology.功能磁共振成像和 CT 生物标志物在肿瘤学中的应用。
Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):562-78. doi: 10.1007/s00259-014-2979-0. Epub 2015 Jan 13.
6
Improving tumour heterogeneity MRI assessment with histograms.利用直方图改善肿瘤异质性的磁共振成像评估
Br J Cancer. 2014 Dec 9;111(12):2205-13. doi: 10.1038/bjc.2014.512. Epub 2014 Sep 30.

本文引用的文献

2
Qualification of imaging biomarkers for oncology drug development.肿瘤药物研发中影像学生物标志物的资格认定。
Eur J Cancer. 2012 Mar;48(4):409-15. doi: 10.1016/j.ejca.2011.11.037. Epub 2012 Jan 5.
8
Phase-contrast X-ray imaging of breast.乳腺的相衬X射线成像
Acta Radiol. 2010 Oct;51(8):866-84. doi: 10.3109/02841851.2010.504742.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验